Growing investment as well as funding by governments and non-government agencies worldwide to exercise control over opioid overdose is the factor basically responsible for the growth of opioid use disorders market. Growing prevalence of opioid use disorder is thus boosting the opioid use disorders industry revenue.
The companies operating in the opioid use disorders market are working toward increasing the production of buprenorphine hydrochloride and naloxone hydrochloride sublingual tablets, which are the generic version of suboxone for treating opioid addiction.
They are also exploring the usage of naloxone nasal sprays as a part of harm reduction therapy for emergency treatment of suspected or known opioid overdose.
Opioid use disorder is amongst the serious health issues worldwide. There are several medication-assisted treatment (MAT) options that are available for helping patients battling this disorder.
The products basically used for treatments that include naltrexone, buprenorphine, and methadone. The consequences of opioid crisis include growing frequency of blood-borne infections and proliferation of bacteria causing heart infections (endocarditis).
These days, organic growth strategies are emphasized. For instance, in April 2020, Amneal Pharmaceuticals, Inc. announced that it had received an abbreviated new drug application (ANDA) approval from the U.S. FDA for generic version of butrans transdermal system.
Amneal Pharmaceuticals, Inc. was granted competitive generic therapy (CGT) designation with 180 days of exclusivity for 7.5 mcg/hr dose.
In August 2022, the U.S. Department of Health and Human Services (HHS) announced the award of US$ 79.1 Mn in overdose prevention grants as part of President Biden’s National Drug Control Strategy, HHS Overdose Prevention Strategy, and Biden-Harris Unity Agenda in order to address opioid overdose epidemic.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per the WHO, nearly 296 million individuals worldwide used drugs atleast once in a year in 2021. It further states that close to 39.5 million individuals were fighting drug disorders in 2021.
As per the Magnitude of Substance Use in India published by the National Drug Dependence Treatment Centre (NDDTC) in February 2019, incidence of use of opioids is 2.1% with about 0.6% of Indians expected to require help for problems related to use of opioids.
As per the CDC, 2.7 million people aged 12 and above were reported to suffer from opioid use disorders.
Need to combat opioid addiction is thus accelerating the opioid use disorders market growth.
The government as well as non-government agencies are organizing awareness campaigns regarding the ill-effects of drug overdose.
The number of opioid addicts is increasing on a significant note, which has prompted them to have an extensive approach toward addressing the problem of drug abuse. Various countries have stepped up for assisting the patients and reducing impact of opioid dependence.
In March 2022, Health and Human Services (HHS) announced funding for opioid use prevention as well as treatment. The basic objective of this move is that of expanding access to medication-assisted treatment for opioid use disorder ad aversion of misuse of prescription drugs.
Continual efforts regarding creation of awareness regarding disadvantages of opioid addiction is thus expanding the opioid use disorders market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest opioid use disorders market analysis, North America dominated the substance abuse disorder landscape in 2023 and the dominance is expected to remain unchanged during the forecast period.
This is attributed to a sizable increase in the number of individuals battling opioid dependency in the U.S. As per an article published by the National Center for Biotechnology Information (NCBI) in 2020, close to 2.1 million individuals suffered from cancer then.
Asia Pacific’s significant opioid use disorders market share is ascribed to increase in awareness amongst the global population with regards to opioid addiction. Besides, rise in healthcare spending is catalyzing the narcotic use disorder treatment landscape.
The key participants in the opioid use disorders market are launching new products in order to strengthen their position.
For instance, in April 2023, the New York State Department of Health (DoH) and New York State Office of Addiction Services and Supports (OASAS) announced that they had launched Buprenorphine Assistance Pilot Program to help with optimization of price of buprenorphine for treatment of opioid use disorders.
Indivior PLC, Alkermes plc, Orexo AB, Titan Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International, Inc., Viatris Inc. (Mylan N.V.), Hikma Pharmaceuticals plc, and Camurus AB are some of the key players covered in the opioid use disorders market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 3.2 Bn |
| Market Forecast (Value) in 2034 | US$ 8.8 Bn |
| Growth Rate (CAGR) | 9.9% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 3.2 Bn in 2023
It is projected to grow at a CAGR of 9.9% from 2024 to 2034
Growing cases of opioid addiction and government & non-government agencies increasingly focusing on creation of awareness
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Indivior PLC, Alkermes plc, Orexo AB, Titan Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International, Inc., Viatris Inc. (Mylan N.V.), Hikma Pharmaceuticals plc, and Camurus AB
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Opioid Use Disorders Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Opioid Use Disorders Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Opioid Use Disorders Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2020-2034
6.3.1. Buprenorphine
6.3.2. Methodone
6.3.3. Naltrexone
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Opioid Use Disorders Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2020-2034
7.3.1. Oral
7.3.2. Parenteral
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Opioid Use Disorders Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Opioid Use Disorders Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Opioid Use Disorders Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2020-2034
10.3.1. Buprenorphine
10.3.2. Methodone
10.3.3. Naltrexone
10.4. Market Value Forecast, by Route of Administration, 2020-2034
10.4.1. Oral
10.4.2. Parenteral
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Opioid Use Disorders Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2020-2034
11.3.1. Buprenorphine
11.3.2. Methodone
11.3.3. Naltrexone
11.4. Market Value Forecast, by Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Opioid Use Disorders Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2020-2034
12.3.1. Buprenorphine
12.3.2. Methodone
12.3.3. Naltrexone
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Opioid Use Disorders Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2020-2034
13.3.1. Buprenorphine
13.3.2. Methodone
13.3.3. Naltrexone
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Opioid Use Disorders Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2020-2034
14.3.1. Buprenorphine
14.3.2. Methodone
14.3.3. Naltrexone
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Indivior PLC
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Alkermes plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Orexo AB
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Titan Pharmaceuticals, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Mallinckrodt Pharmaceuticals
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. BioDelivery Sciences International, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Viatris Inc. (Mylan N.V.)
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Hikma Pharmaceuticals plc
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Camurus AB
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Opioid Use Disorders Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 02: Global Opioid Use Disorders Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 03: Global Opioid Use Disorders Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Opioid Use Disorders Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Opioid Use Disorders Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Opioid Use Disorders Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 07: North America Opioid Use Disorders Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 08: North America Opioid Use Disorders Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 09: Europe Opioid Use Disorders Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Opioid Use Disorders Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 11: Europe Opioid Use Disorders Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 12: Europe Opioid Use Disorders Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Asia Pacific Opioid Use Disorders Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Opioid Use Disorders Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 15: Asia Pacific Opioid Use Disorders Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 16: Asia Pacific Opioid Use Disorders Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 17: Latin America Opioid Use Disorders Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Opioid Use Disorders Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 19: Latin America Opioid Use Disorders Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 20: Latin America Opioid Use Disorders Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Middle East & Africa Opioid Use Disorders Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Opioid Use Disorders Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 23: Middle East & Africa Opioid Use Disorders Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 24: Middle East & Africa Opioid Use Disorders Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Opioid Use Disorders Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Opioid Use Disorders Market Revenue (US$ Bn), by Drug Type, 2023
Figure 03: Global Opioid Use Disorders Market Value Share, by Drug Type, 2023
Figure 04: Global Opioid Use Disorders Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 05: Global Opioid Use Disorders Market Value Share, by Route of Administration, 2023
Figure 06: Global Opioid Use Disorders Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 07: Global Opioid Use Disorders Market Value Share, by Distribution Channel, 2023
Figure 08: Global Opioid Use Disorders Market Value Share, by Region, 2023
Figure 09: Global Opioid Use Disorders Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Opioid Use Disorders Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 11: Global Opioid Use Disorders Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Opioid Use Disorders Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 13: Global Opioid Use Disorders Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 14: Global Opioid Use Disorders Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 15: Global Opioid Use Disorders Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 16: Global Opioid Use Disorders Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Opioid Use Disorders Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Opioid Use Disorders Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Opioid Use Disorders Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Opioid Use Disorders Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Opioid Use Disorders Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 22: North America Opioid Use Disorders Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 23: North America Opioid Use Disorders Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 24: North America Opioid Use Disorders Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Opioid Use Disorders Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 26:North America Opioid Use Disorders Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 27: Europe Opioid Use Disorders Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Opioid Use Disorders Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Opioid Use Disorders Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Opioid Use Disorders Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 31: Europe Opioid Use Disorders Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 32: Europe Opioid Use Disorders Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Europe Opioid Use Disorders Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Opioid Use Disorders Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 35: Europe Opioid Use Disorders Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 36: Asia Pacific Opioid Use Disorders Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Opioid Use Disorders Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Opioid Use Disorders Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Opioid Use Disorders Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 40: Asia Pacific Opioid Use Disorders Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 41: Asia Pacific Opioid Use Disorders Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 42: Asia Pacific Opioid Use Disorders Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Opioid Use Disorders Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 44: Asia Pacific Opioid Use Disorders Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 45: Latin America Opioid Use Disorders Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Opioid Use Disorders Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Opioid Use Disorders Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Opioid Use Disorders Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 49: Latin America Opioid Use Disorders Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Latin America Opioid Use Disorders Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Latin America Opioid Use Disorders Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Opioid Use Disorders Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 53: Latin America Opioid Use Disorders Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 54: Middle East & Africa Opioid Use Disorders Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Opioid Use Disorders Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Opioid Use Disorders Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Opioid Use Disorders Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 58: Middle East & Africa Opioid Use Disorders Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 59: Middle East & Africa Opioid Use Disorders Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 60: Middle East & Africa Opioid Use Disorders Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Opioid Use Disorders Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 62: Middle East & Africa Opioid Use Disorders Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Opioid Use Disorders Market
